REMARC: Lenalidomide vs Placebo as Maintenance Therapy in Patients With DLBCL Following R-CHOP Induction

December 3-6, 2016; San Diego, California
Lenalidomide maintenance therapy in elderly patients with DLBCL significantly improved PFS compared with placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 456 KB
Released: December 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Interactive online tool providing expert treatment recommendations for newly diagnosed and relapsed/refractory follicular lymphoma from CCO

John M. Burke, MD Ian W. Flinn, MD, PhD Christopher R. Flowers, MD, MS John P. Leonard, MD Jeff P. Sharman, MD Released: March 1, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue